Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/58056
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde Noronha, Thiago Rodrigo [UNIFESP]
dc.contributor.authorMitne-Neto, Miguel
dc.contributor.authorChauffaille, Maria de Lourdes [UNIFESP]
dc.date.accessioned2020-09-01T13:21:02Z-
dc.date.available2020-09-01T13:21:02Z-
dc.date.issued2017
dc.identifierhttp://dx.doi.org/10.1136/jim-2017-000566
dc.identifier.citationJournal Of Investigative Medicine. London, v. 65, n. 8, p. 1155-1158, 2017.
dc.identifier.issn1081-5589
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/58056-
dc.description.abstractKaryotype (KT) aberrations are important prognostic factors for acute myeloid leukemia (AML); however, around 50% of cases present normal results. Single nucleotide polymorphism array can detect chromosomal gains, losses or uniparental disomy that are invisible to KT, thus improving patients' risk assessment. However, when both tests are normal, important driver mutations can be detected by the use of next-generation sequencing (NGS). Fourteen adult patients with AML with normal cytogenetics were investigated by NGS for 19 AML-related genes. Every patient presented at least one mutation: DNMT3A in nine patients; IDH2 in six; IDH1 in three; NRAS and NPM1 in two; and TET2, ASXL1, PTPN11, and RUNX1 in one patient. No mutations were found in FLT3, KIT, JAK2, CEBPA, GATA2, TP53, BRAF, CBL, KRAS, and WT1 genes. Twelve patients (86%) had at least one mutation in genes related with DNA methylation (DNMT3A, IDH1, IDH2, and TET2), which is involved in regulation of gene expression and genomic stability. All patients could be reclassified based on genomic status and nine had their prognosis modified. In summary, NGS offers insights into the molecular pathogenesis and biology of cytogenetically normal AML in Brazilian patients, indicating that the prognosis could be further stratified by different mutation combinations. This study shows a different frequency of mutations in Brazilian population that should be confirmed.en
dc.description.sponsorshipResearch and Development from Fleury Group
dc.format.extent1155-1158
dc.language.isoeng
dc.publisherBmj Publishing Group
dc.relation.ispartofJournal Of Investigative Medicine
dc.rightsAcesso restrito
dc.subjectacute myeloid leukemiaen
dc.subjectcytogenetically normalen
dc.subjectsingle nucleotide polymorphism arrayen
dc.subjecttargeted next generation sequencingen
dc.titleMutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classificationen
dc.typeArtigo
dc.description.affiliationUniv Fed Sao Paulo, Div Hematol, BR-4037002 Sao Paulo, Brazil
dc.description.affiliationFleury Grp, Res & Dev, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Hematol, BR-4037002 Sao Paulo, Brazil
dc.identifier.doi10.1136/jim-2017-000566
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000419439300011
dc.coverageLondon
dc.citation.volume65
dc.citation.issue8
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.